



Synergy Pharmaceuticals, Inc.

Corporate Profile

STATISTICS

OTC BB: SGYP.OB
 Fiscal Year: Dec. 31
 Common shares o/s (mm): 88

COMPANY OVERVIEW

Headquarters: New York, NY
 Transfer Agent: StockTrans, Inc.
 Auditors: BDO Seidman, LLP

BUSINESS FOCUS

Synergy is focused on drugs to treat gastro-intestinal disorders and diseases.

MANAGEMENT

Gary S. Jacob, Ph.D. President & CEO

20+ years experience in drug discovery and development at Monsanto, G.D. Searle, and Oxford University. Ph.D., U. Wisconsin - Madison.

Gabriele M. Cerrone, MBA Chairman

Founder of number of biotechnology and diagnostic companies, including Fermavir Pharmaceuticals (now part of Inhibitex, Inc.), TrovaGene, Inc. and Callisto Pharmaceuticals, Inc. Managing partner of Panetta Partners Ltd, a Colorado limited partnership.

Kunwar Shailubhai, MBA, Ph.D. Chief Scientific Officer

Over 15 years experience in oncology at NIH and G.D. Searle. Ph.D., University of Baroda, India; MBA from U. Missouri.

Craig C. Talluto, Ph.D., Executive Director, Clinical Development. Over 10 years of experience at Amgen, Roche and Kos, Ph.D., University of Miami, FL.

Bernard F. Denoyer, MBA, CPA, SVP, Finance. Over 25 years experience in META Group, Envionetics, Gartner Group and Ernst & Young. MBA in finance, Columbia Business School.

ABOUT SYNERGY PHARMACEUTICALS

Synergy Pharmaceuticals, Inc. (SGYP.OB) is a public, development-stage biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) conditions and diseases.

The Company's headquarters are in New York City, and it also operates a research laboratory in Doylestown, PA supporting Synergy's research and drug development activities.

Our patented drug candidates, currently in clinical and non-clinical development, were discovered and developed in-house by Synergy scientists. Synergy's drug development program and patent estate are based on a class of synthetic peptides designed to mimic uroguanylin, a human hormone that regulates intestinal fluid transport.

Synergy's lead drug candidate SP-304, a guanylyl cyclase C (GC-C) receptor agonist, is currently in a Phase 2a clinical trial in chronic constipation (CC) patients, and will also be developed to treat constipation-predominant irritable bowel syndrome (IBS-C). A second drug, SP-333, is in pre-clinical development for GI diseases.


PIPELINE

SP-304

SP-304 completed its initial Phase I safety trial in volunteers, and recently began a Phase IIa 14-day, repeated-oral-dose, placebo-controlled, clinical trial in chronic constipation patients.

SP-333

SP-333, a GC-C receptor agonist, is in preclinical development to treat ulcerative colitis. An IND is planned for 2010.



DEVELOPMENT PROGRAMS

SP-304 Development Program

- **Chemistry and biology:** SP-304 is an analog of the natural gastrointestinal peptide uroguanylin, a key regulator of intestinal function. SP-304 works locally in the GI tract by activating the GC-C receptor, a receptor on the inside lining of the intestine, promoting fluid and ion transport in the gastrointestinal (GI) tract. The drug, administered orally, acts locally in the gut and shows virtually no systemic absorption into the bloodstream, suggesting that the drug will have an excellent safety profile.
- **Development:** SP-304 completed a single-dose Phase I clinical trial in volunteers in late 2008. A Phase 2a randomized, placebo-controlled, 14-day, repeated-oral-dose trial in CC patients was initiated in early 2010, and the company plans to follow this trial with Phase 2b trials in CC and IBS-C in 2011.
- **Market opportunity:** CC and IBS-C are functional GI disorders that afflict millions of sufferers worldwide. There is only one product approved for these indications at present in the US.

Chronic Constipation

Chronic constipation is a common gastrointestinal disorder affecting up to 26 million Americans, roughly 5 million of whom have a severe condition necessitating relief. The incidence of this disorder is similar in other developed countries, including Europe and Japan. Patients with chronic constipation often experience hard stools, straining during bowel movements and insufficient bowel movements per week. People with chronic constipation typically experience serious discomfort, adversely affecting their ability to work and their quality of life.

Irritable Bowel Syndrome

Up to one in six adults experience inflammatory bowel syndrome (IBS) in the US, a condition marked by disturbed bowel function and abdominal pain. IBS patients fall into three categories with different symptoms; diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), and mixed or alternating disorder (IBS-M). The number of individuals in each category is about 33% of the total number of IBS patients. An estimated 10 million people in the US suffer from IBS-C, with about 2.5 million experiencing at the severe form of the condition. IBS (all forms) accounts for approximately 12% of all adult visits to primary care physicians in the US. An equivalent number of people, roughly 10 million, suffer from the condition in the EU.

SP-333 Development Program

- **Chemistry and biology:** SP-333 is a second-generation GCC-C receptor analog of uroguanylin designed as our lead drug candidate to treat ulcerative colitis (UC) an inflammatory bowel disease.
- **Development:** SP-333 is currently in pre-clinical development and we plan to file an Investigational New Drug application (IND) to treat UC in late 2010, and initiate a trial in volunteers.

RECENT NEWS

March 19, 2010

[Synergy Pharmaceuticals Initiates Phase 2a Clinical Trial of SP-304 in Patients with Chronic Constipation](#)

January 22, 2010

[Synergy Pharmaceuticals to Present at the 8th Annual Bio-Partnering North America \(BPN\) Conference in Vancouver, BC, Canada](#)

December 11, 2009

[Synergy Pharmaceuticals Raises \\$8.6 Million in Common Stock Financing](#)

October 8, 2009

[Synergy Pharmaceuticals Announces Appointment of Dr. Alan F. Joslyn to Board of Directors](#)

October 5, 2009

[Synergy Pharmaceuticals to Present at the 17th Annual Bio-Partnering Europe Conference in London, UK](#)

July 7, 2009

[Synergy Pharmaceuticals Raises \\$7.09 Million in Common Stock Financing](#)

May 26, 2009

[Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorders at Upcoming Conference](#)

December 9, 2008

[Synergy Pharmaceuticals Successfully Completes Phase 1 Trials in Volunteers](#)

CONTACT INFORMATION

Corporate office:

Synergy Pharmaceuticals Inc.
420 Lexington Avenue, Suite # 1609
New York, NY 10170, USA.

Tel: +1-212-297-0020

Fax: +1-212-297-0019

Web: www.synergypharma.com

For more information, please contact Gary S Jacob, Ph.D., CEO:
gjacob@synergypharma.com
Tel: +1-212-297-0020

Information presented in this document is not to be construed as an offer to sell or a solicitation to buy any securities referred to herein. The information is considered reliable but not guaranteed to accuracy or completeness. This information is to be considered 'forward' looking and involves a number of risks and uncertainties as defined under the Private Securities Reform Act